SCHEMBL2260416

SCHEMBL2260416

O=C(Nc1c(Br)cc(C(c2ccc(Cl)cc2)(n2cc(Cl)cn2)C(F)(F)F)cc1Br)c1cccc(NC(=O)c2cccnc2Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
PTGES O14684 1/20 0.41
RHOC P08134 1/20 0.40
RHOA P61586 1/20 0.40
RXFP1 Q9HBX9 3/20 0.39
CSF1R P07333 2/20 0.39
ALDH1A1 P00352 1/20 0.39
AURKA O14965 1/20 0.38
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
NR1H4 Q96RI1 2/20 0.38
PPARA Q07869 1/20 0.38
EPHX2 P34913 1/20 0.38
POLB P06746 2/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KCNK3 O14649 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18023941 0.84 MEN1 (0.53) MEN1KMT2APTGESRHOCRHOA
SCHEMBL18023939 0.84 MEN1 (0.53) MEN1KMT2APTGESRHOCRHOA
SCHEMBL18023983 0.83 MEN1 (0.52) MEN1KMT2APTGESRHOCRHOA
SCHEMBL13497564 0.83 RHOC (0.35) MEN1KMT2ARHOCRHOAALDH1A1
SCHEMBL1815240 0.82 PTGS1 (0.42) MEN1KMT2ARHOCRHOAALDH1A1
SCHEMBL1829876 0.81 MEN1 (0.54) MEN1KMT2APTGESRHOCRHOA
SCHEMBL1811552 0.80 F2 (0.48) MEN1KMT2ARXFP1ALDH1A1POLB
SCHEMBL18023940 0.80 MEN1 (0.56) MEN1KMT2APTGESRHOCRHOA
SCHEMBL1767081 0.79 MEN1 (0.53) MEN1KMT2APTGESRHOCRHOA
SCHEMBL18023938 0.79 MEN1 (0.57) MEN1KMT2APTGESRHOCRHOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 MEN1 3469/4885KMT2A 676/4885PTGES 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.